Search results
Results from the WOW.Com Content Network
Amgen shares trade at just 13.4 times forward earnings, a remarkable discount to the S&P 500's multiple of nearly 24. This valuation gap seems overdone, given Amgen's cash-generating power.
Shares of Amgen (NASDAQ: AMGN) are down by 6% in the last 30 days as I write this -- a larger-than-normal amount for a large pharma company's stock to fall, especially considering that the market ...
Amgen (NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months. Despite a string of solid earnings reports from the biotechnology giant ...
The biotech industry can be volatile even for relatively large companies. Amgen (NASDAQ: AMGN), one of the more prominent names in the game, just reminded us all of that fact. Let's find out what ...
On Tuesday, Amgen Inc. (NASDAQ:AMGN) reported second-quarter sales of $8.39 billion, up 20% year over year and beating the consensus of $8.33 billion. Product sales grew 20%, driven by 26% volume ...
While Amgen's (NASDAQ: AMGN) shares have underperformed the market over the past 12 months, climbing 19.7% compared to the market's unusually large gain of 35.6%, there's no shortage of reasons to ...
The company's stock is trading 13.9 times its forward 12-month earnings estimates, compared with a forward price-to-earnings ratio of 34.2 for Novo Nordisk and 48.49 for Eli Lilly.
The biotech Amgen (NASDAQ: AMGN) isn't exactly known as a growth stock. Over the past few years, the company's organic revenue hasn't been increasing at a particularly impressive rate.